A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

被引：57

作者：

Konopleva, Marina ^{[1
]}

Pollyea, Daniel A. ^{[2
]}

Potluri, Jalaja ^{[3
]}

Chyla, Brenda J. ^{[3
]}

Busman, Todd ^{[3
]}

McKeegan, Evelyn ^{[3
]}

Salem, Ahmed ^{[3
]}

Zhu, Ming ^{[3
]}

Ricker, Justin L. ^{[3
]}

Blum, William ^{[4
]}

DiNardo, Courtney D. ^{[1
]}

Dunbar, Martin ^{[3
]}

Kirby, Rachel ^{[3
]}

Falotico, Nancy ^{[3
]}

Leverson, Joel D. ^{[3
]}

Humerickhouse, Rod A. ^{[3
]}

Mabry, Mack ^{[3
]}

Stone, Richard M. ^{[5
]}

Kantarjian, Hagop M. ^{[1
]}

Letai, Anthony G. ^{[5
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Colorado, Ctr Canc, Aurora, CO USA

[3] AbbVie Inc, N Chicago, IL USA

[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.118.118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), in acute myeloid leukemia patients
Popovic, Relja
Daver, Naval
Ruvolo, Vivian
Chen, Ken
Wang, Zixing
Huang, Xin
Mabry, Mack
Potluri, Jalaja
McKeegan, Evelyn
Konopleva, Marina
Chyla, Brenda J.
CANCER RESEARCH, 2016, 76
[2] A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Gerecitano, John F.
Roberts, Andrew W.
Seymour, John F.
Wierda, William G.
Kahl, Brad S.
Pagel, John M.
Puvvada, Soham
Kipps, Thomas J.
Anderson, Mary Ann
Dunbar, Martin
Zhu, Ming
Gressick, Lori
Wagner, Lindsay
Kim, Su Young
Enschende, Sari Heitner
Humerickhouse, Rod A.
Davids, Matthew S.
BLOOD, 2015, 126 (23)
[3] BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia
Hogdal, Leah
Chyla, Brenda
McKeegan, Evelyn
Leverson, Joel
Potluri, Jalaja
Falotico, Nancy
Ricker, Justin
Humerickhouse, Rod
Mabry, Mack
Foight, Glenna
Keating, Amy
Galinsky, Ilene
Stone, Richard
DeAngelo, Daniel
Konopleva, Marina
Letai, Anthony
CANCER RESEARCH, 2015, 75
[4] Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
Han, Lina
Zhang, Qi
Shi, Ce
Leverson, Joel
Dail, Monique
Phillips, Darren C.
Chen, Jun
Jin, Sha S.
Jacamo, Rodrigo Omar
Daver, Naval
Jabbour, Elias J.
Kantarjian, Hagop M.
Andreeff, Michael
Sampath, Deepak
Konopleva, Marina
BLOOD, 2015, 126 (23)
[5] VENETOCLAX (ABT-199/GDC-0199) COMBINED WITH RITUXIMAB INDUCES DEEP RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Roberts, A. W.
Ma, S.
Brander, D.
Kipps, T. J.
Barrientos, J. C.
Davids, M. S.
Anderson, M. A.
Choi, M.
Tam, C.
Magee, L.
Kreutzer, J.
Singh, R.
Kim, J.
Dimovski, B.
Mason-Bright, T.
Prine, B.
Zhu, M.
Humerickhouse, R. A.
Seymour, J. F.
HAEMATOLOGICA, 2015, 100 : 154 - 154
[6] VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE I SAFETY AND EFFICACY
Kumar, S.
Vij, R.
Kaufman, J. L.
Mikhael, J.
Facon, T.
Moreau, P.
Amiot, M.
Alzate, S.
Morris, L.
Ross, J.
Dunbar, M.
Zhu, M.
Agarwal, S.
Leverson, J.
Enschede, S.
Humerickhouse, R.
Touzeau, C.
HAEMATOLOGICA, 2015, 100 : 256 - 257
[7] Venetoclax (ABT-199/GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia
Ma, Shuo
Roberts, Andrew W.
Brander, Danielle
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Choi, Michael
Tam, Constantine
Magee, Lisa
Kreutzer, Jennifer
Kim, Jennifer
Dimovski, Belinda
Mason-Bright, Tanita
Prine, Betty
Zhu, Ming
Humerickhouse, Rod A.
Seymour, John F.
LEUKEMIA & LYMPHOMA, 2015, 56 : 21 - 21
[8] A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
DiNardo, Courtney
Pollyea, Daniel
Pratz, Keith
Thirman, Michael J.
Letai, Anthony
Frattini, Mark
Jonas, Brian
Leverson, Joel
Zhu, Ming
Dunbar, Martin
Falotico, Nancy
Kirby, Rachel
Agarwal, Suresh
Mabry, Mack
Potluri, Jalaja
Humerickhouse, Rod A.
Kantarjian, Hagop M.
Konopleva, Marina
BLOOD, 2015, 126 (23)
[9] Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
Han, Lina
Zhang, Qi
Shi, Ce
Cavazos, Antonio
Ruvolo, Vivian R.
Leverson, Joel D.
Dail, Monique
Phillips, Darren C.
Chen, Jun
Jin, Sha S.
Jacamo, Rodrigo
Daver, Naval
Jabbour, Elias
Kantarjian, Hagop M.
Andreeff, Michael
Sampath, Deepak
Konopleva, Marina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S282 - S282
[10] Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Roberts, Andrew W.
Ma, Shuo
Brander, Danielle M.
Kipps, Thomas J.
Barrientos, Jacqueline C.
Davids, Matthew S.
Anderson, Mary Ann
Tam, Constantine
Mason-Bright, Tanita
Rudersdorf, Nikita K.
Gressick, Lori
Yang, Jianning
Munasinghe, Wijith
Zhu, Ming
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Seymour, John F.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →